Compass Therapeutics (CMPX) Cash & Equivalents (2023 - 2025)
Historic Cash & Equivalents for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $46.8 million.
- Compass Therapeutics' Cash & Equivalents rose 2518.4% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year increase of 2518.4%. This contributed to the annual value of $44.1 million for FY2024, which is 8181.86% up from last year.
- Latest data reveals that Compass Therapeutics reported Cash & Equivalents of $46.8 million as of Q3 2025, which was up 2518.4% from $23.4 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Cash & Equivalents peaked at $46.8 million during Q3 2025, and registered a low of $19.3 million during Q2 2023.
- In the last 3 years, Compass Therapeutics' Cash & Equivalents had a median value of $30.4 million in 2023 and averaged $32.5 million.
- In the last 5 years, Compass Therapeutics' Cash & Equivalents skyrocketed by 8181.86% in 2024 and then tumbled by 429.36% in 2025.
- Over the past 3 years, Compass Therapeutics' Cash & Equivalents (Quarter) stood at $24.2 million in 2023, then skyrocketed by 81.82% to $44.1 million in 2024, then increased by 6.2% to $46.8 million in 2025.
- Its Cash & Equivalents was $46.8 million in Q3 2025, compared to $23.4 million in Q2 2025 and $41.6 million in Q1 2025.